Merck’s KEYTRUDA Monotherapy Reduces Risk of Disease Progression or Death by 43% in Advanced or Recurrent dMMR Endometrial Cancer
RAHWAY, New Jersey, United States — October 26, 2026 Merck, known as MSD outside the United States and Canada,...
Merck, MSD, KEYTRUDA, Pembrolizumab, Endometrial Cancer, Endometrial Carcinoma, dMMR, Mismatch Repair Deficient, Immunotherapy, PD-1 Inhibitor, KEYNOTE-C93, Phase III
Advertisement
Advertisement
